Mirovian (Metformin Hydrochloride)

• Mirovian (metformin) is indicated for conditions related to impaired glucose metabolism and insulin resistance.
• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to improve overall glycemic control.
• Prediabetes (impaired fasting glucose): delays progression to overt diabetes when combined with lifestyle modification.
• Polycystic ovary syndrome: reduces insulin resistance and may help restore ovulatory function.
• Gestational diabetes (off‑label use): assists in controlling maternal blood glucose under specialist supervision.

• Metformin exerts its antidiabetic effect primarily by inhibiting hepatic gluconeogenesis, thereby decreasing endogenous glucose production. It also enhances peripheral insulin sensitivity by increasing glucose uptake in skeletal muscle and adipose tissue, and modestly reduces intestinal glucose absorption. The drug activates AMP‑activated protein kinase (AMPK), a key regulator of cellular energy homeostasis, which contributes to its metabolic actions. Additionally, metformin may improve lipid profiles and exert modest anti‑inflammatory effects.

Metformin is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, and diarrhea.
• Metallic taste: transient alteration in taste perception.
• Decreased appetite: reduced food intake leading to mild weight loss.
• Vitamin B12 deficiency: gradual reduction in serum B12 levels with long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening accumulation of lactate.
• Severe hypoglycemia: usually when combined with insulin or sulfonylureas.
• Hepatotoxicity: abnormal liver enzymes indicating liver injury.
• Skin reactions: rash, erythema, or Stevens‑Johnson syndrome.

When prescribing metformin, clinicians should consider several precautionary measures to minimise risk.

• Renal function: assess creatinine clearance before initiation and periodically thereafter.
• Hepatic impairment: avoid use in patients with significant liver disease.
• Cardiovascular status: monitor for signs of heart failure, especially in high‑risk patients.
• Alcohol consumption: advise limiting intake to reduce lactic acidosis risk.
• Concomitant medications: review for drugs that may affect renal clearance or increase lactate production.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Metformin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: can precipitate acute renal failure, increasing lactic acidosis risk.
• Cimetidine: may raise metformin plasma concentrations, heightening toxicity.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: combined use may affect renal function, requiring monitoring.
• Diuretics: can reduce renal clearance of metformin.
• Beta‑blockers: may mask hypoglycaemia symptoms.
• Antiretroviral protease inhibitors: may increase metformin levels.